Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trialOnyema Ogbuagu, Jared M. Baeten, Edwin DeJesus et al.|The Lancet HIV|2023Cited by 71
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studiesMounir Ait‐Khaled, Jean van Wyk, Juan Sierra Madero et al.|HIV Research & Clinical Practice|2021Cited by 11
1024. Impact of Treatment Adherence on Efficacy of DTG/3TC and DTG + TDF/FTC: Pooled Analysis of the GEMINI 1 and 2 Clinical TrialsMounir Ait‐Khaled, Hung‐Chin Tsai, Choy Man et al.|Open Forum Infectious Diseases|2020Cited by 1